Skip to main content

Table 4 Multivariable logistic regression analyses for TNFi-insensitivity and poor response to a TNFi using DAS28-ESR

From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

CategoryTNFi insensitivity (N = 91)Insufficient response (N = 453)
OR95% CIpOR95% CIp
GenderFemale1 (reference)1 (reference)
Male0.720.40–1.290.270.490.35–0.69< 0.01
Age category 501 (reference)1 (reference)
51–601.260.69–2.320.451.781.22–2.60< 0.01
61–700.720.36–1.420.341.721.18–2.510.01
 710.990.51–1.900.971.911.30–2.81< 0.01
Duration (year)< 0.51 (reference)1 (reference)
0.5–20.370.14–0.960.040.940.44–2.010.87
2–50.290.10–0.840.020.870.40–1.910.73
≥ 50.140.050.41< 0.010.900.43–1.900.79
DAS28-ESR at week 0 3.21 (reference)1 (reference)
> 3.22.621.54–4.47< 0.012.531.91–3.36< 0.01
RF positivity*0.990.59–1.650.971.280.95–1.730.11
Concomitant use of GC1.490.882.510.141.341.01–1.790.05
Dose of MTX (mg/week)01 (reference)1 (reference)
1–61.020.38–2.720.970.710.41–1.220.22
7–90.690.31–1.570.380.730.47–1.150.17
10–150.730.34–1.560.410.630.40–0.970.04
> 150.480.20–1.140.100.560.34–0.910.02
Failure in > 2 csDMARDs1.640.67–4.040.281.090.74–1.630.66
BiologicsIFX1 (reference)1 (reference)
ETA1.350.40–4.490.631.170.66–2.090.59
ADA1.510.66–3.440.330.810.55–1.200.29
GLM3.710.67–20.690.141.550.55–4.320.41
CZP1.130.22–5.660.890.460.19–1.120.09
PhaseI + II1 (reference)1 (reference)
III1.490.82–2.700.190.710.52–0.970.03
  1. DAS28 disease activity score for 28 joints, ESR erythrocyte sedimentation rate, MTX methotrexate, GC glucocorticoid, OR odds ratio, CI confidence interval
  2. *RF > 20 IU/mL was defined as positive
  3. p < 0.05
\